m6A-modification of cyclin D1 and c-myc IRESs in glioblastoma controls ITAF activity and resistance to mTOR inhibition

By sjmartinez • April 16, 2023

Benavides-Serrato A, Saunders JT, Kumar S, Holmes B, Benavides KE, Bashir MT, Nishimura RN, Gera J. m⁶A-modification of cyclin D1 and c-myc IRESs in glioblastoma controls ITAF activity and resistance to mTOR inhibition. Cancer Lett. 2023 Apr 13:216178. doi: 10.1016/j.canlet.2023.216178. Epub ahead of print. PMID: 37061119.

Tags: Drug resistance, Glioblastoma, Hematology/Oncology, IRES, ITAF, mTOR inhibitors, N(6)-methyladenosine modification, Publications, Veterans Administration

Liquid Biopsy of Circulating Tumor Cells and DNA in the Context of PSMA Radiopharmaceutical Therapy

Holzgreve A, Mona CE, Kimura K, Li X, Zhu Y, Tseng HR, Lee JK, Drakaki A, Garraway IP, Rettig MB, Calais J, Salavati A. Liquid[...]

Cumulative burden of depression and domain-specific cognitive impairment over time in the women’s interagency HIV study: A marginal structural model approach

Tejera CH, Duggal P, Diaz M, Topper E, Gustafson D, Jamieson BD, Maki PM, Sharma A, Spence AB, Weber KM, Weinstein AM, Jones DL, Fazeli[...]

Characterization of the Fecal Metabolome in Patients With Early Systemic Sclerosis

Young AC, Andréasson K, Labus J, Matulionis N, Jacobs JP, Christofk H, Volkmann ER. Characterization of the Fecal Metabolome in Patients With Early Systemic Sclerosis.[...]